$5.27 Billion is the total value of Orbimed Advisors's 116 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 42.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ASND | Sell | ASCENDIS PHARMA A Ssponsored adr | $358,231,000 | -19.1% | 3,719,173 | -3.3% | 6.80% | -0.9% |
| TCDA | TRICIDA INC | $343,098,000 | -21.8% | 11,114,280 | 0.0% | 6.51% | -4.2% | |
| BSX | Sell | BOSTON SCIENTIFIC CORP | $214,383,000 | -26.1% | 5,268,700 | -22.0% | 4.07% | -9.5% |
| ALEC | Sell | ALECTOR INC | $180,716,000 | -27.8% | 12,532,329 | -4.9% | 3.43% | -11.6% |
| PRVL | PREVAIL THERAPEUTICS INC | $169,740,000 | -7.0% | 13,822,463 | 0.0% | 3.22% | +14.0% | |
| MRK | Sell | MERCK & CO INC | $164,496,000 | -23.7% | 1,954,100 | -24.0% | 3.12% | -6.5% |
| ALXN | Sell | ALEXION PHARMACEUTICALS INC | $162,902,000 | -35.4% | 1,663,285 | -13.6% | 3.09% | -20.9% |
| SWTX | New | SPRINGWORKS THERAPEUTICS INC | $160,569,000 | – | 7,406,307 | +100.0% | 3.05% | – |
| VRTX | Sell | VERTEX PHARMACEUTICALS INC | $143,397,000 | -19.7% | 846,400 | -13.0% | 2.72% | -1.6% |
| NBIX | Sell | NEUROCRINE BIOSCIENCES INC | $141,939,000 | -8.3% | 1,575,170 | -14.1% | 2.69% | +12.3% |
| EW | Sell | EDWARDS LIFESCIENCES CORP | $111,670,000 | -15.5% | 507,800 | -29.0% | 2.12% | +3.6% |
| ISRG | Sell | INTUITIVE SURGICAL INC | $111,010,000 | +0.6% | 205,600 | -2.2% | 2.11% | +23.3% |
| TPTX | Buy | TURNING POINT THERAPEUTICS I | $103,224,000 | -1.2% | 2,745,327 | +6.9% | 1.96% | +21.1% |
| TMO | Sell | THERMO FISHER SCIENTIFIC INC | $102,498,000 | -24.6% | 351,900 | -24.0% | 1.94% | -7.6% |
| IOVA | IOVANCE BIOTHERAPEUTICS INC | $100,980,000 | -25.8% | 5,548,326 | 0.0% | 1.92% | -9.1% | |
| NTRA | Sell | NATERA INC | $98,404,000 | +10.7% | 3,000,128 | -7.0% | 1.87% | +35.6% |
| AVDR | AVEDRO INC | $96,251,000 | +15.6% | 4,240,128 | 0.0% | 1.83% | +41.6% | |
| INSP | INSPIRE MED SYS INC | $89,760,000 | +0.6% | 1,471,000 | 0.0% | 1.70% | +23.2% | |
| THOR | SYNTHORX INC | $86,497,000 | +20.4% | 5,316,355 | 0.0% | 1.64% | +47.6% | |
| NXTC | NEXTCURE INC | $83,635,000 | +105.9% | 2,711,013 | 0.0% | 1.59% | +152.3% | |
| DCPH | Sell | DECIPHERA PHARMACEUTICALS IN | $83,512,000 | +2.4% | 2,460,571 | -32.0% | 1.58% | +25.4% |
| WMGI | Sell | WRIGHT MED GROUP N V | $79,162,000 | -36.6% | 3,837,250 | -8.4% | 1.50% | -22.3% |
| EHTH | Buy | EHEALTH INC | $74,632,000 | -4.7% | 1,117,414 | +22.8% | 1.42% | +16.7% |
| BHC | Sell | BAUSCH HEALTH COS INC | $72,374,000 | -23.3% | 3,312,300 | -11.5% | 1.37% | -6.0% |
| LOGC | LOGICBIO THERAPEUTICS INC | $69,906,000 | -16.8% | 6,466,783 | 0.0% | 1.33% | +1.8% | |
| EXEL | EXELIXIS INC | $69,200,000 | -17.2% | 3,912,900 | 0.0% | 1.31% | +1.4% | |
| ABT | Sell | ABBOTT LABS | $68,810,000 | -12.8% | 822,400 | -12.3% | 1.31% | +6.9% |
| PTCT | Sell | PTC THERAPEUTICS INC | $66,250,000 | -29.5% | 1,958,900 | -6.3% | 1.26% | -13.7% |
| REGN | Buy | REGENERON PHARMACEUTICALS | $63,275,000 | -6.3% | 228,100 | +5.7% | 1.20% | +14.8% |
| SRPT | Buy | SAREPTA THERAPEUTICS INC | $63,069,000 | -49.9% | 837,349 | +1.1% | 1.20% | -38.6% |
| ANTM | Sell | ANTHEM INC | $61,129,000 | -40.1% | 254,600 | -29.6% | 1.16% | -26.6% |
| DXCM | Buy | DEXCOM INC | $57,308,000 | +45.5% | 384,000 | +46.1% | 1.09% | +78.2% |
| MGTX | Buy | MEIRAGTX HOLDINGS PLC | $53,418,000 | -23.2% | 3,349,060 | +29.5% | 1.01% | -5.8% |
| HUM | New | HUMANA INC | $46,481,000 | – | 181,800 | +100.0% | 0.88% | – |
| PRNB | PRINCIPIA BIOPHARMA INC | $45,345,000 | -14.9% | 1,605,713 | 0.0% | 0.86% | +4.2% | |
| ARVN | Sell | ARVINAS INC | $45,153,000 | -23.3% | 2,095,283 | -21.8% | 0.86% | -6.0% |
| BLU | New | BELLUS HEALTH INC NEW | $45,129,000 | – | 7,025,832 | +100.0% | 0.86% | – |
| BOLD | Sell | AUDENTES THERAPEUTICS INC | $44,609,000 | -31.2% | 1,588,069 | -7.3% | 0.85% | -15.7% |
| CI | Buy | CIGNA CORP NEW | $44,262,000 | +11.2% | 291,600 | +15.4% | 0.84% | +36.4% |
| TORC | RESTORBIO INC | $42,701,000 | -13.3% | 4,830,387 | 0.0% | 0.81% | +6.2% | |
| MRTX | New | MIRATI THERAPEUTICS INC | $41,693,000 | – | 535,143 | +100.0% | 0.79% | – |
| MYOK | Sell | MYOKARDIA INC | $40,835,000 | -14.7% | 783,032 | -18.0% | 0.78% | +4.4% |
| ATNX | Sell | ATHENEX INC | $40,253,000 | -47.1% | 3,308,920 | -13.8% | 0.76% | -35.1% |
| TNDM | Buy | TANDEM DIABETES CARE INC | $39,186,000 | +6.4% | 664,390 | +16.4% | 0.74% | +30.5% |
| RARE | Buy | ULTRAGENYX PHARMACEUTICAL IN | $35,692,000 | +606.1% | 834,313 | +948.0% | 0.68% | +767.9% |
| ARGX | ARGENX SEsponsored adr | $35,373,000 | -19.5% | 310,400 | 0.0% | 0.67% | -1.5% | |
| HARP | HARPOON THERAPEUTICS INC | $33,418,000 | +5.1% | 2,446,409 | 0.0% | 0.63% | +28.6% | |
| QURE | Sell | UNIQURE NV | $33,047,000 | -52.9% | 839,600 | -6.5% | 0.63% | -42.3% |
| CRNX | CRINETICS PHARMACEUTICALS IN | $30,671,000 | -39.8% | 2,039,282 | 0.0% | 0.58% | -26.3% | |
| ARQL | Buy | ARQULE INC | $26,538,000 | +141.0% | 3,701,273 | +270.1% | 0.50% | +194.7% |
| IQV | New | IQVIA HLDGS INC | $26,142,000 | – | 175,000 | +100.0% | 0.50% | – |
| XTNT | XTANT MED HLDGS INC | $26,148,000 | -5.3% | 9,207,012 | 0.0% | 0.50% | +15.9% | |
| ONCE | Buy | SPARK THERAPEUTICS INC | $23,750,000 | +5.5% | 244,900 | +11.4% | 0.45% | +29.2% |
| PRTA | Sell | PROTHENA CORP PLC | $23,693,000 | -26.9% | 3,022,117 | -1.4% | 0.45% | -10.4% |
| AMGN | AMGEN INC | $23,628,000 | +5.0% | 122,100 | 0.0% | 0.45% | +28.7% | |
| AGLE | Buy | AEGLEA BIOTHERAPEUTICS INC | $22,036,000 | +48.6% | 2,865,524 | +32.3% | 0.42% | +81.7% |
| ADVM | Buy | ADVERUM BIOTECHNOLOGIES INC | $21,871,000 | -6.2% | 4,012,969 | +104.7% | 0.42% | +15.0% |
| VRCA | VERRICA PHARMACEUTICALS INC | $21,841,000 | +27.0% | 1,479,733 | 0.0% | 0.41% | +55.6% | |
| OBSV | OBSEVA SA | $21,704,000 | -26.3% | 2,605,531 | 0.0% | 0.41% | -9.6% | |
| CRSP | New | CRISPR THERAPEUTICS AGnamen akt | $21,167,000 | – | 516,400 | +100.0% | 0.40% | – |
| KRYS | Sell | KRYSTAL BIOTECH INC | $20,903,000 | -19.1% | 601,950 | -6.2% | 0.40% | -0.8% |
| GILD | Sell | GILEAD SCIENCES INC | $20,668,000 | -23.8% | 326,100 | -18.8% | 0.39% | -6.7% |
| ALC | ALCON INC | $20,493,000 | -5.5% | 351,380 | 0.0% | 0.39% | +15.8% | |
| CRVS | Buy | CORVUS PHARMACEUTICALS INC | $20,370,000 | -17.0% | 6,767,584 | +3.1% | 0.39% | +1.8% |
| SCPH | SCPHARMACEUTICALS INC | $20,016,000 | +84.0% | 3,409,865 | 0.0% | 0.38% | +126.2% | |
| IBB | New | ISHARES TRput | $19,900,000 | – | 200,000 | +100.0% | 0.38% | – |
| AUPH | AURINIA PHARMACEUTICALS INC | $18,856,000 | -18.8% | 3,531,002 | 0.0% | 0.36% | -0.6% | |
| NVO | NOVO-NORDISK A Sadr | $17,061,000 | +1.3% | 330,000 | 0.0% | 0.32% | +24.1% | |
| ZLAB | Sell | ZAI LAB LTDadr | $16,628,000 | -59.2% | 514,000 | -56.0% | 0.32% | -49.9% |
| SVA | SINOVAC BIOTECH LTD | $16,611,000 | 0.0% | 2,839,500 | 0.0% | 0.32% | +22.6% | |
| APLS | Sell | APELLIS PHARMACEUTICALS INC | $15,029,000 | -67.5% | 623,859 | -65.8% | 0.28% | -60.2% |
| ALPN | ALPINE IMMUNE SCIENCES INC | $14,537,000 | -5.9% | 3,670,955 | 0.0% | 0.28% | +15.5% | |
| FOMX | Sell | FOAMIX PHARMACEUTICALS LTD | $14,558,000 | +17.7% | 4,788,896 | -7.8% | 0.28% | +44.5% |
| KALA | KALA PHARMACEUTICALS INC | $13,119,000 | -40.4% | 3,447,840 | 0.0% | 0.25% | -27.0% | |
| TAK | TAKEDA PHARMACEUTICAL CO LTDsponsored ads | $12,900,000 | -2.8% | 750,000 | 0.0% | 0.24% | +18.9% | |
| RETA | Buy | REATA PHARMACEUTICALS INCput | $12,044,000 | +27.7% | 150,000 | +50.0% | 0.23% | +56.8% |
| XFOR | X4 PHARMACEUTICALS INC | $11,903,000 | -15.3% | 936,493 | 0.0% | 0.23% | +3.7% | |
| KPTI | Sell | KARYOPHARM THERAPEUTICS INC | $10,254,000 | -45.6% | 1,065,900 | -66.1% | 0.20% | -33.2% |
| INSM | New | INSMED INC | $9,919,000 | – | 562,300 | +100.0% | 0.19% | – |
| NABRIVA THERAPEUTICS PLC | $9,289,000 | -17.7% | 4,644,600 | 0.0% | 0.18% | +0.6% | ||
| RARX | New | RA PHARMACEUTICALS INC | $8,914,000 | – | 376,894 | +100.0% | 0.17% | – |
| BIIB | Sell | BIOGEN INC | $8,428,000 | -58.9% | 36,200 | -58.7% | 0.16% | -49.7% |
| AVRO | Buy | AVROBIO INC | $8,058,000 | +367.4% | 570,700 | +438.4% | 0.15% | +466.7% |
| SIBN | Sell | SI BONE INC | $7,457,000 | -62.8% | 422,000 | -57.2% | 0.14% | -54.2% |
| PSNL | Buy | PERSONALIS INC | $7,100,000 | -12.8% | 483,842 | +61.3% | 0.14% | +7.1% |
| PBYI | Buy | PUMA BIOTECHNOLOGY INC | $6,853,000 | -13.6% | 636,600 | +2.0% | 0.13% | +5.7% |
| EHTH | New | EHEALTH INCcall | $6,679,000 | – | 100,000 | +100.0% | 0.13% | – |
| ALDR | New | ALDER BIOPHARMACEUTICALS INCput | $6,601,000 | – | 350,000 | +100.0% | 0.12% | – |
| XENE | XENON PHARMACEUTICALS INC | $5,720,000 | -8.6% | 634,812 | 0.0% | 0.11% | +12.4% | |
| VRNA | VERONA PHARMA PLCsponsored ads | $5,714,000 | -10.4% | 1,250,396 | 0.0% | 0.11% | +9.1% | |
| HCAT | New | HEALTH CATALYST INC | $5,682,000 | – | 179,598 | +100.0% | 0.11% | – |
| CNST | CONSTELLATION PHARMCETICLS I | $5,400,000 | -47.4% | 835,842 | 0.0% | 0.10% | -35.8% | |
| ARNA | ARENA PHARMACEUTICALS INC | $5,035,000 | -21.9% | 110,000 | 0.0% | 0.10% | -4.0% | |
| SELB | SELECTA BIOSCIENCES INC | $5,038,000 | -2.3% | 2,879,064 | 0.0% | 0.10% | +20.0% | |
| EPIX | New | ESSA PHARMA INC | $4,960,000 | – | 1,471,853 | +100.0% | 0.09% | – |
| SYBX | SYNLOGIC INC | $4,649,000 | -74.8% | 2,029,996 | 0.0% | 0.09% | -69.2% | |
| NTLA | INTELLIA THERAPEUTICS INC | $4,373,000 | -18.5% | 327,600 | 0.0% | 0.08% | 0.0% | |
| CTIC | CTI BIOPHARMA CORP | $4,185,000 | -2.6% | 5,000,000 | 0.0% | 0.08% | +17.9% | |
| SRPT | New | SAREPTA THERAPEUTICS INCcall | $3,766,000 | – | 50,000 | +100.0% | 0.07% | – |
| ARPO | AERPIO PHARMACEUTICALS INC | $3,531,000 | -25.3% | 5,193,946 | 0.0% | 0.07% | -8.2% | |
| ACAD | Sell | ACADIA PHARMACEUTICALS INC | $3,460,000 | +27.0% | 96,143 | -5.6% | 0.07% | +57.1% |
| AMRN | Sell | AMARIN CORP PLCspons adr new | $3,352,000 | -75.9% | 221,100 | -69.2% | 0.06% | -70.2% |
| MRSN | MERSANA THERAPEUTICS INC | $2,988,000 | -61.0% | 1,891,119 | 0.0% | 0.06% | -52.1% | |
| MNLO | Sell | MENLO THERAPEUTICS INC | $2,968,000 | -26.4% | 662,600 | -1.6% | 0.06% | -9.7% |
| CRIS | New | CURIS INC | $2,781,000 | – | 1,241,494 | +100.0% | 0.05% | – |
| ICPT | New | INTERCEPT PHARMACEUTICALS IN | $2,137,000 | – | 32,200 | +100.0% | 0.04% | – |
| ADAP | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $2,039,000 | -62.4% | 1,350,655 | 0.0% | 0.04% | -53.6% | |
| NVUS | NOVUS THERAPEUTICS INC | $1,974,000 | -38.6% | 3,183,314 | 0.0% | 0.04% | -26.0% | |
| PBYI | New | PUMA BIOTECHNOLOGY INCcall | $1,615,000 | – | 150,000 | +100.0% | 0.03% | – |
| SNDX | SYNDAX PHARMACEUTICALS INC | $1,584,000 | -19.8% | 212,000 | 0.0% | 0.03% | -3.2% | |
| SPRO | Sell | SPERO THERAPEUTICS INC | $1,492,000 | -74.5% | 140,709 | -72.3% | 0.03% | -68.9% |
| CVM | New | CEL SCI CORPput | $1,118,000 | – | 125,000 | +100.0% | 0.02% | – |
| RUBY | New | RUBIUS THERAPEUTICS INCput | $785,000 | – | 100,000 | +100.0% | 0.02% | – |
| KALV | New | KALVISTA PHARMACEUTICALS INC | $449,000 | – | 38,733 | +100.0% | 0.01% | – |
| BLRX | New | BIOLINERX LTDsponsored ads | $183,000 | – | 69,240 | +100.0% | 0.00% | – |
| MDGS | MEDIGUS LTDsponsored ads | $26,000 | -29.7% | 15,000 | 0.0% | 0.00% | -100.0% | |
| BLRX | Exit | BIOLINERX LTDsponsored ads | $0 | – | -1,038,600 | -100.0% | -0.01% | – |
| FLXN | Exit | FLEXION THERAPEUTICS INC | $0 | – | -89,919 | -100.0% | -0.02% | – |
| NVTRQ | Exit | NUVECTRA CORP | $0 | – | -350,000 | -100.0% | -0.02% | – |
| MRNS | Exit | MARINUS PHARMACEUTICALS INC | $0 | – | -398,101 | -100.0% | -0.03% | – |
| APLS | Exit | APELLIS PHARMACEUTICALS INCcall | $0 | – | -75,000 | -100.0% | -0.03% | – |
| DVAX | Exit | DYNAVAX TECHNOLOGIES CORP | $0 | – | -583,500 | -100.0% | -0.04% | – |
| RLM | Exit | REALM THERAPEUTICS PLCsponsored ads | $0 | – | -1,021,484 | -100.0% | -0.04% | – |
| STOK | Exit | STOKE THERAPEUTICS INC | $0 | – | -130,000 | -100.0% | -0.06% | – |
| MDCO | Exit | MEDICINES CO | $0 | – | -151,515 | -100.0% | -0.09% | – |
| ADPT | Exit | ADAPTIVE BIOTECHNOLOGIES COR | $0 | – | -120,000 | -100.0% | -0.09% | – |
| BMRN | Exit | BIOMARIN PHARMACEUTICAL INCput | $0 | – | -75,000 | -100.0% | -0.10% | – |
| BMRN | Exit | BIOMARIN PHARMACEUTICAL INC | $0 | – | -75,000 | -100.0% | -0.10% | – |
| FOLD | Exit | AMICUS THERAPEUTICS INC | $0 | – | -518,309 | -100.0% | -0.10% | – |
| GILD | Exit | GILEAD SCIENCES INCcall | $0 | – | -100,000 | -100.0% | -0.10% | – |
| ASMB | Exit | ASSEMBLY BIOSCIENCES INC | $0 | – | -523,600 | -100.0% | -0.11% | – |
| PFE | Exit | PFIZER INCput | $0 | – | -250,000 | -100.0% | -0.17% | – |
| SYK | Exit | STRYKER CORP | $0 | – | -54,000 | -100.0% | -0.17% | – |
| IMMU | Exit | IMMUNOMEDICS INC | $0 | – | -818,200 | -100.0% | -0.18% | – |
| PRQR | Exit | PROQR THRAPEUTICS N V | $0 | – | -1,382,502 | -100.0% | -0.20% | – |
| ABBV | Exit | ABBVIE INCcall | $0 | – | -200,000 | -100.0% | -0.22% | – |
| RYTM | Exit | RHYTHM PHARMACEUTICALS INC | $0 | – | -787,300 | -100.0% | -0.27% | – |
| TAK | Exit | TAKEDA PHARMACEUTICAL CO LTDcall | $0 | – | -1,000,000 | -100.0% | -0.27% | – |
| GNFT | Exit | GENFIT S Aads | $0 | – | -1,125,607 | -100.0% | -0.34% | – |
| BMY | Exit | BRISTOL MYERS SQUIBB COcall | $0 | – | -500,000 | -100.0% | -0.35% | – |
| ENDP | Exit | ENDO INTL PLC | $0 | – | -6,165,464 | -100.0% | -0.39% | – |
| MYL | Exit | MYLAN N V | $0 | – | -1,373,305 | -100.0% | -0.40% | – |
| CLVS | Exit | CLOVIS ONCOLOGY INC | $0 | – | -1,913,234 | -100.0% | -0.44% | – |
| SPY | Exit | SPDR S&P 500 ETF TRput | $0 | – | -100,000 | -100.0% | -0.45% | – |
| CDNA | Exit | CAREDX INC | $0 | – | -827,600 | -100.0% | -0.46% | – |
| VRAY | Exit | VIEWRAY INC | $0 | – | -5,149,019 | -100.0% | -0.70% | – |
| ILMN | Exit | ILLUMINA INC | $0 | – | -140,200 | -100.0% | -0.80% | – |
| BMY | Exit | BRISTOL MYERS SQUIBB CO | $0 | – | -1,345,200 | -100.0% | -0.94% | – |
| A | Exit | AGILENT TECHNOLOGIES INC | $0 | – | -893,200 | -100.0% | -1.03% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-14
About Orbimed Advisors
Orbimed Advisors is a leading healthcare-focused investment firm that manages over $16 billion in assets. The firm was founded in 1998 by Samuel Isaly, who has over 50 years of experience in the healthcare industry. Isaly is widely regarded as a pioneer in the field of healthcare investing and has been recognized for his contributions to the industry by numerous organizations.
Orbimed Advisors has a team of over 100 professionals, including investment professionals, research analysts, and operational experts. The firm has offices in New York, San Francisco, Shanghai, and Mumbai, and invests in companies across the healthcare spectrum, including biotechnology, pharmaceuticals, medical devices, and healthcare services.
The firm's investment philosophy is based on a deep understanding of the healthcare industry and a rigorous approach to due diligence. Orbimed Advisors seeks to identify companies with innovative technologies and strong management teams that have the potential to transform the healthcare landscape.
Orbimed Advisors has a strong track record of success, with numerous successful investments in companies such as Juno Therapeutics, Spark Therapeutics, and Kite Pharma. The firm's leadership team, which includes CEO Sven Borho, COO Jonathan Silverstein, and Chief Investment Officer Carl Gordon, has decades of experience in the healthcare industry and is widely respected for their expertise and insights.
Overall, Orbimed Advisors is a leading healthcare investment firm that has a proven track record of success and a deep understanding of the healthcare industry. Investors looking to gain exposure to the healthcare sector may want to consider Orbimed Advisors as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC | 42 | Q3 2023 | 5.0% |
| VERTEX PHARMACEUTICALS INC | 42 | Q3 2023 | 3.7% |
| THERMO FISHER SCIENTIFIC INC | 42 | Q3 2023 | 3.2% |
| SINOVAC BIOTECH LTD | 41 | Q3 2023 | 7.2% |
| NEUROCRINE BIOSCIENCES INC | 41 | Q3 2023 | 2.7% |
| BOSTON SCIENTIFIC CORP | 40 | Q3 2023 | 5.6% |
| BRISTOL-MYERS SQUIBB CO | 40 | Q2 2023 | 5.2% |
| AMGEN INC | 40 | Q3 2023 | 5.5% |
| INTUITIVE SURGICAL INC | 40 | Q3 2023 | 3.8% |
| GILEAD SCIENCES INC | 39 | Q3 2023 | 5.5% |
View Orbimed Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ikena Oncology, Inc. | September 21, 2023 | 2,189,111 | 5.2% |
| Galecto, Inc. | September 18, 2023 | 749,557 | 2.8% |
| PMV Pharmaceuticals, Inc. | August 23, 2023 | 6,563,077 | 13.5% |
| Gracell Biotechnologies Inc. | August 11, 2023 | 7,641,531 | 8.0% |
| Xtant Medical Holdings, Inc. | August 03, 2023 | 73,114,592 | 56.7% |
| Turnstone Biologics Corp. | July 24, 2023 | 3,099,265 | 13.4% |
| Prelude Therapeutics Inc | May 24, 2023 | 15,716,642 | 28.6% |
| VectivBio Holding AG | May 24, 2023 | 5,156,561 | 7.7% |
| Fusion Pharmaceuticals Inc. | May 16, 2023 | 2,930,670 | 4.6% |
| Verona Pharma plc | May 16, 2023 | 3,777,778 | 4.8% |
View Orbimed Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-26 |
| 4 | 2024-04-23 |
| 4 | 2024-04-18 |
| 4 | 2024-04-15 |
| 3/A | 2024-04-12 |
| SC 13D/A | 2024-04-12 |
| 4 | 2024-04-05 |
| SC 13D/A | 2024-04-04 |
| 3 | 2024-04-03 |
| SC 13D | 2024-03-28 |
View Orbimed Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.